Trial Profile
A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Lundbeck A/S
- 18 Jun 2009 Actual initiation date changed from 1 Jun 2005 to1 Sep 2005 as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 20 May 2009 Additional location Wales identified as reported by United Kingdom Clinical Research Network.